AI In Clinical Trials Market Size, Revenue Share, Insights & Future Outlook

AI In Clinical Trials Market Size

The global market for AI In Clinical Trials was valued at US$ 52.3 million in the year 2024 and is projected to reach a revised size of US$ 82.4 million by 2031, growing at a CAGR of 6.8% during the forecast period.

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-29K15279/Global_AI_In_Clinical_Trials_Market_Research_Report_2023?utm_source=openpr&utm_medium=referral

By Type
• Software
• Service

By Application
• Pharmaceutical and Biotechnology Companies
• Contract Research Organization

Key Companies
Intel, The International Business Machines Corporation(IBM), Koninklijke Philips N.V., ConcertAl, Saama Technologies LLC, Samaa Technologies, Owkin Inc., Numerate, Neuroute, AiCure, Ardigen, Unlearn Al, PathAl, Exscentia, Aitia Infotech Pvt Ltd., Euretos, VeriSIM Life, Envisagenics, NURITAs, BioSymetrics, BioAge Labs lInc

The AI In Clinical Trials Market is experiencing strong market growth as pharmaceutical and biotechnology companies increasingly adopt artificial intelligence to enhance efficiency, reduce costs, and accelerate drug development. Market trends indicate rising demand for predictive analytics, patient recruitment optimization, and real-time data monitoring. The overall market size is expanding as AI-driven solutions improve trial design, compliance, and outcome reliability, reshaping the landscape of clinical research.

By type, Software solutions currently hold the largest market share, driven by robust adoption of AI platforms for data analysis, trial simulation, and process automation. Service-based offerings are emerging as the fastest-growing segment, supported by increasing outsourcing of AI implementation, clinical data management, and consulting services to specialized providers. Both segments contribute to market growth by enabling organizations to harness AI capabilities effectively across clinical trial operations.

Based on application, Pharmaceutical and Biotechnology Companies dominate the market share, leveraging AI to optimize trial protocols, patient stratification, and biomarker analysis. Contract Research Organizations (CROs) are witnessing rapid growth as they increasingly integrate AI tools to enhance trial efficiency, regulatory compliance, and client service delivery. Together, these applications drive adoption and innovation across the clinical trial ecosystem.

Leading companies such as Intel, IBM, and Koninklijke Philips N.V. hold significant market share through advanced AI platforms, strategic partnerships, and global deployment capabilities. Other key players, including ConcertAl, Saama Technologies, Owkin Inc., Numerate, and Neuroute, are enhancing market growth by providing specialized AI software, predictive modeling, and trial analytics. Emerging firms like AiCure, Ardigen, Unlearn AI, PathAI, and Exscientia contribute through innovative approaches in patient engagement, machine learning models, and adaptive trial design.

Regionally, North America leads the AI in Clinical Trials market, supported by advanced healthcare infrastructure, AI research investment, and high pharmaceutical R&D activity. Europe maintains steady growth through regulatory support and adoption of digital trial methodologies. Asia-Pacific is emerging as the fastest-growing region, driven by expanding clinical research capacity, rising pharmaceutical investments, and growing acceptance of AI-driven innovations. The market forecast indicates continued expansion, fueled by digital transformation, data-driven insights, and the increasing role of AI in optimizing clinical development processes globally.

View Full Report: https://reports.valuates.com/request/sample/QYRE-Auto-29K15279/Global_AI_In_Clinical_Trials_Market_Research_Report_2023

Email Id:
Please reach us at sales@valuates.com

Address:
Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.